NASDAQ$ORGO

Organogenesis Holdings Inc · Q3 2021 earnings

Q3 2021 earnings · · Investor relations

Briefing

Organogenesis reported third quarter 2021 financial results, with revenue up 13% year-over-year and net income of $12.6 million.

Organogenesis Holdings Inc. reported a 13% increase in net revenue for the third quarter of 2021, reaching $113.8 million. Net income was $12.6 million, and adjusted EBITDA was $21.7 million. The company reaffirmed its full-year revenue guidance.

  • Net revenue increased by 13% to $113.8 million compared to Q3 2020.
  • Advanced Wound Care product revenue increased by 19% to $107.3 million.
  • Surgical & Sports Medicine product revenue decreased by 41% to $6.4 million.
  • Net income was $12.6 million, a decrease compared to $20.8 million in Q3 2020.

Headline financials

Total Revenue

$114M

Previous: $101M+12.9%
EPS (adj)

$0.10

Previous: $0.19-47.4%
Capital Expenditures

-$26M

Previous: -$12.3M-112.0%
Free Cash Flow

-$13.4M

Previous: $8.67M-254.7%
Net Income

$12.6M

Previous: $20.9M-39.9%
Operating Income

$16.3M

Previous: $23M-29.2%
Gross Profit

$87.6M

Previous: $77.8M+12.5%
Cash & Equivalents

$102M

Previous: $36.5M+180.0%
Total Assets

$370M

Previous: $246M+50.3%
Stock-Based Comp

$1.04M

Previous: $486K+114.2%

Revenue & EPS history

Organogenesis · Revenue · Quarterly

$114M

Q3 2021+12.9%vs Q3 2020
Beat estimate in 8 of 14 quarters(57%)
ActualEstimate

Revenue by segment

Organogenesis · $114M total across 2 segments · Q3 2021

  • Advanced Wound Care
    $107M+19.2%
  • Surgical & Sports Medicine
    $6.4M-40.8%

Forward guidance

For the twelve months ended December 31, 2021, the Company now expects net revenue of between $458 million and $470 million.

Tailwinds

  • Net revenue of between $458 million and $470 million, representing an increase of approximately 35% to 39% year-over-year
  • Net revenue from Advanced Wound Care products of between $425 million and $434 million, representing an increase of approximately 44% to 47% year-over-year
  • Net revenue from the sale of PuraPly products of between $196 million and $204 million, representing an increase of approximately 33% to 39% year-over-year
  • GAAP net income positive for the twelve months ended December 31, 2021.
  • Adjusted EBITDA positive for the twelve months ended December 31, 2021.

Headwinds

  • Net revenue from Surgical & Sports Medicine products of between $33 million and $36 million, representing a decrease of approximately 18% to 24% year-over-year

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2021

Historical avgQ3 2021

+2.8%

Avg return

Earnings day

+3.2%

Avg return

5 days after

+0.5%

Avg return

30 days after

47%

17 / 36 earnings

Positive

+102.3%

Q4 2024

Best reaction

-42.4%

Q1 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-2.0%-6.2%-5.9%
Q4 2025-13.8%-22.4%-38.1%
Q3 2025+44.1%+66.6%+21.9%
Q1 2025-42.4%-43.6%-43.3%
Q4 2024+102.3%+95.8%+46.6%
Q3 2024+26.6%+10.3%+0.9%
Q2 2024+2.0%+6.4%-1.2%
Q1 2024+31.2%+23.2%+19.0%
Q4 2023-16.3%-20.3%-18.6%
Q3 2023+6.8%+22.9%+62.4%
Q2 2023-25.7%-27.0%-31.6%
Q1 2023+29.7%+43.2%+81.1%
Q4 2022+11.0%-2.9%-13.1%
Q3 2022-18.3%-11.5%-17.7%
Q2 2022-25.2%-26.6%-44.0%
Q1 2022+4.6%+9.8%-9.3%
Q4 2021+18.1%+15.6%+2.4%
Q3 2021-6.4%-5.0%-16.1%
Q2 2021+1.9%+2.5%+8.2%
Q1 2021-15.3%-11.3%-28.7%
Q4 2020+3.8%+8.5%+31.4%
Q3 2020+8.2%+5.2%+20.2%
Q2 2020+0.7%+1.5%+3.2%
Q1 2020-9.9%-18.8%+4.2%
Q4 2019-16.2%+11.6%+23.5%
Q3 2019+10.3%+8.8%-36.1%
Q2 2019-4.7%-10.8%+26.5%
Q1 2019-0.4%+1.0%+0.7%
Q4 2018-3.0%-5.3%-16.8%
Q4 2017-3.0%-5.3%-16.8%
Q2 2018+0.3%+0.2%+0.1%
Q1 2018+0.0%+0.4%+0.3%
Q3 2017+0.1%+0.1%-1.0%
Q2 2017+0.0%+0.1%+1.5%
Q1 2017-0.3%-0.3%+0.5%
Q4 2016+0.0%+0.0%+0.0%
Q3 2016
Q2 2016
Q1 2016

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro